http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-MU8602991-U
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1d90bc3925193a8ced29c5b00246df72 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 |
filingDate | 2006-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a5297dd64297847d3b9b67b215956a6d |
publicationDate | 2008-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | BR-MU8602991-U |
titleOfInvention | medicine "candesartan + metformin" in combination form for cardiovascular disease |
abstract | CANDESARTAN + METFORMINE "MEDICINE" COMBINED FOR CARDIO VASCULAR DISEASES, summarize the combination of two drugs used against cardiovascular disease are the leading cause of death in our country. There is a clear correlation between weight gain and overweight with risk of cardiovascular disease. Overweight predisposes to these diseases due to abnormalities in lipid metabolism, glucose and blood pressure. Insulin resistance / hyperinsulinemia appears to be a risk factor independent of other associated risk factors such as obesity, hyperlipidemia and hypertension in both men and women. Insulin and insulin-like growth factors stimulate smooth muscle cell activity and are involved in atherogenesis and even restenosis following coronary repair by angioplasty. Other effects of insulin are related to the mechanisms that contribute to the development of both hypertension and dyslipidemia. "CANDESARTAN + METFORMINE" MEDICINE COMBINED FOR CARDIO VASCULAR DISEASES, decreasing insulin resistance, blood pressure, weight gain and improving the lipid profile of this patient would greatly reduce the likelihood of cardiovascular events and consequently the death of this nature in our population. |
priorityDate | 2006-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 110.